Merck Millipore Granted Patent for Selective Layering Method that Sets Standard for Consistency of Virus Filtration Performance
![](/46/pdcnewsitem/03/43/12/KIS2qY8bhCqhq1m.jpg)
Merck Millipore, the Life Science division of Merck, has been granted a US patent for developing a selective layering method that significantly improves the consistency of virus filtration performance. The method is used to manufacture Merck Millipore's Viresolve Pro Device, a virus filtration technology that offers highly productive parvovirus clearance for monoclonal antibodies and therapeutic proteins. As a result of selective layering, the Viresolve Pro Device provides an industry-leading performance consistency superior to other virus filtration devices currently on the market.
The Viresolve Pro Device uses a dual-layer PES membrane designed to simultaneously deliver high parvovirus log reduction value (LRV), capacity and flux. Using the now patented method, the top and bottom membrane layers are selected from different segments of the normal membrane population and optimally paired to drive performance consistency. This optimal pairing strategy reduces device-to-device throughput performance variability by about half compared to random pairing, while also increasing the average throughput performance. The result is strong batch-to-batch consistency in virus retention, permeability and throughput capacity.
"This new patent reflects Merck Millipore's ongoing commitment to delivering innovation to our customers in biopharmaceutical manufacturing," said Udit Batra, President and CEO of Merck Millipore. "Our team of experts developed this methodology to significantly improve upon industry standards for virus clearance unit operations. The resulting performance consistency enables drug manufacturers to accelerate the process of developing drug therapies for patients in need."
Introduced in 2008, the Viresolve Pro Device has been proven to enable robust parvovirus clearance and a highly productive virus filtration unit operation. The device offers high mass capacity, as well as optional capacity enhancement with the use of an adsorptive polishing step. In addition, its single-use flowpaths require no cleaning validation and the processing typically takes less than four hours at scale, making the device quick and easy to install and use.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance